News

Jul 03, 2020

Watch Hosts Danielle Hicks and Bonnie Addario speak with Dr. Jacob Sands and Dr. William Mayfield about the progress that's been made over the last 50 years in lung cancer treatment. Their conversation looks at the incredible advances in everything from the number of driver mutations with FDA-approved targeted therapies (including for KRAS and HER2 that have drugs performing well currently in clinical trials), radiation, surgery, chemotherapy (and corresponding drugs to help better tolerate side effects) and screening.

Jul 03, 2020

Artificial intelligence (AI) holds promise for enabling earlier detection of pancreatic cancer, which is crucial to saving lives. The potential of AI is showcased in a study to be presented at the ESMO World Congress on Gastrointestinal Cancer. Overall, 12 in every 100,000 people develop pancreatic cancer. This means that screening everyone would be inefficient and would expose many people to unnecessary tests and potential side-effects. Between 70-80% of patients are diagnosed at an advanced stage when it is too late for curative treatment and five years after diagnosis, just 6% of patients have survived.

Jul 03, 2020

Researchers at the University of Alberta have found a way to deliver anti-cancer drugs with more precision, which could increase the effectiveness of many cancer treatments. U of A oncologist Frank Wuest altered the surface of nanoparticles, which are well suited to deliver drugs, with epidermal growth factor (EGF), a peptide that binds to EGF receptors on cancer cells.

Journal Abstracts

Jul 03, 2020

Adriana C. Gamboa et.al. conducted a study to assess the latest evidence guiding the histiotype‐specific management of extremity/truncal and retroperitoneal Soft‐tissue sarcomas with regard to surgery, radiation, and chemotherapy. The researchers concluded that continued collaborative efforts will allow studies to be both sufficiently large and sufficiently focused to generate evidence that is clinically meaningful in specific Soft‐tissue sarcomas patient populations.

Jul 03, 2020

Jingjing Miao et.al. conducted a study to investigate the outcomes with a reduced primary clinical target volume and radiation dose for early-stage nasopharyngeal carcinoma. The researchers concluded that decreased primary clinical target volume margins and radiation doses can achieve long-term tumor control with mild late toxicities for patients with early-stage nasopharyngeal carcinoma.

Jul 03, 2020

E. G. Garcia et.al. conducted a study to identify protein tyrosine phosphatase type 4 A3 (PRL3) as a collaborating oncogenic driver in T-cell acute lymphoblastic leukemia. The researchers concluded that new roles for PRL3 as a collaborating oncogenic driver in human T-cell acute lymphoblastic leukemia and suggest that therapeutic targeting of the PRL3 phosphatase will likely be a useful treatment strategy for T-cell acute lymphoblastic leukemia.

Recent Articles

Jul 03, 2020

Lung cancer screening (LCS) by low-dose computed tomography (LDCT) does not examine spirometry in eligible patients, but study findings published this week in the Annals of the American Thoracic Society suggest that adding this feature could improve the high burden of undiagnosed chronic obstructive pulmonary disease (COPD) and emphysema. Based on prior trial findings, LCS by LDCT has been found to significantly reduce the relative risk of lung cancer-specific and all-cause mortality by 20.0% and 6.7%. When it comes to eligibility, those who undergo LCS are typical of older age or former smokers, which are 2 of the strongest predictors of the development of COPD.

 

Jul 03, 2020

Adriana C. Gamboa et.al. conducted a study to assess the latest evidence guiding the histiotype‐specific management of extremity/truncal and retroperitoneal Soft‐tissue sarcomas with regard to surgery, radiation, and chemotherapy. The researchers concluded that continued collaborative efforts will allow studies to be both sufficiently large and sufficiently focused to generate evidence that is clinically meaningful in specific Soft‐tissue sarcomas patient populations.

Jul 03, 2020

Lung cancer screening (LCS) by low-dose computed tomography (LDCT) does not examine spirometry in eligible patients, but study findings published this week in the Annals of the American Thoracic Society suggest that adding this feature could improve the high burden of undiagnosed chronic obstructive pulmonary disease (COPD) and emphysema. Based on prior trial findings, LCS by LDCT has been found to significantly reduce the relative risk of lung cancer-specific and all-cause mortality by 20.0% and 6.7%. When it comes to eligibility, those who undergo LCS are typical of older age or former smokers, which are 2 of the strongest predictors of the development of COPD.

 

Clinical Research

Jun 01, 2020

The purpose of this study is to find the most effective dose of radiation therapy to give to breast tumors in a shorter period of time, prior to standard partial mastectomy/axillary surgery.

Jun 01, 2020

This research study is being done to understand how patients with chronic cancer pain take their long-acting opioid medications and to develop an intervention to enhance cancer pain management.

Feb 27, 2020

Christopher G. Brennan-Jones et.al. identified specific strategies which have shown effectiveness in reducing workplace noise. These include implementation of stricter legislation and also stress upon the need for training in the proper use of earplugs and earmuffs so as to reduce noise exposure to safe levels. 

Feb 27, 2020

Christopher G. Brennan-Jones et.al. identified specific strategies which have shown effectiveness in reducing workplace noise. These include implementation of stricter legislation and also stress upon the need for training in the proper use of earplugs and earmuffs so as to reduce noise exposure to safe levels. 

Feb 27, 2020

Daniel G. Whitney et.al. conducted a study to determine prevalence of major noncommunicable diseases in young adults with pediatric-onset disabilities and compared it in adults without pediatric onset disabilities. The researchers found that young adults with pediatric onset disabilities showed an early onset of several noncommunicable diseases. They were contributors to global and national burden of disease and mortality.

Jan 31, 2020

This is the first study where BAY1163877 is given to humans. Impact of the study is to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme (no placebo group) to determine the safety, tolerability and maximum tolerated dose (MTD) of BAY1163877.

Jan 31, 2020

The present study will be a randomized trial investigating the impact of e-cigarette device type on reinforcement value and use among current smokers. Current smokers (n=100) will be randomly assigned to either a control group that does not receive an e-cigarette or one of two e-cigarette types: a customizable tank, or a pod. 

Publications

Jun 26, 2020

In patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), a once-daily oral regimen of ibrutinib and venetoclax was associated with deep molecular remissions in both bone marrow and peripheral blood, including in patients with high-risk disease, according to investigators in phase 2 CAPTIVATE MRD trial.

Jun 04, 2020

Georgios Tsakonas et.al. conducted a study to understand the alterations in gene expression in brain metastasis versus primary tumour as it may increase aggressiveness and impair therapeutic efforts. The researchers concluded  identified a unique gene downregulation pattern in brain metastases compared with primary tumours. This finding may explain the lower intracranial efficacy of systemic therapy, especially immunotherapy, in brain metastasis of patients with non–small-cell lung cancer. 

Jun 01, 2020

Advance in Cancer Prevention addresses all types of cancer, how cancer forms in the body, and their prevention. It focuses on Cancer Vaccines, Chemotherapy, Radioactive Iodine Therapy, Breast Reconstruction Surgery, Mammography, Chemoprevention, aromatase inhibitors, Scintimammography, Oncoplastic surgery, Sumoylation, Dietary Supplements, Cancer Screening, Cancer and Nutrition, Exercise and Cancer, Alternative Cancer Medicines, Stem cell transplants for cancer prevention, Naturopathic Treatments, Clinical Naturopathy, Cancer Prevention from nuts.

Jan 29, 2020

This highly respected and frequently cited journal is a prime source of information in the area of fetal and neonatal research. Original papers present research on all aspects of neonatology, fetal medicine and developmental biology. These papers encompass both basic science and clinical research including randomised trials, observational studies and epidemiology.

Jan 29, 2020

Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents. Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes. 

Jan 29, 2020

Journal of Diabetes Investigation is the core diabetes journal from Asia; the official journal of the Asian Association for the Study of Diabetes. The journal publishes original research, country reports, commentaries, reviews, mini-reviews, case reports, letters, as well as editorials and news. The Journal of Diabetes Investigation includes aspects of prevention, treatment, as well as molecular aspects and pathophysiology.

Jan 29, 2020

Hepatobiliary Surgery and Nutrition focuses on new findings in hepatopancreatobiliary disease and nutrition, and to provide current and practical information on diagnosis, prevention and clinical investigations. Specific areas of interest include, but not limited to, surgical techniques, clinical and basic researches, transplantation and other therapies, NASH, NAFLD, targeted drug, gut microbiota, metabolism, cancer immunity, genomics, nutrition and dietetics, etc.

Videos

Jul 03, 2020

Dr. Pasi Janne, Director of Dana-Farber Cancer Institute’s Lowe Center for Thoracic Oncology and Belfer Center for Applied Cancer Science, and colleagues discuss how COVID-19 is changing the screening, management, and treatment of thoracic cancer, including:

  • The impact on lung cancer screening
  • The role of telemedicine in caring for cancer patients
  • Managing clinical trials 
Jul 03, 2020

Breast cancer patients who are overweight or obese might benefit less from treatment with docetaxel, a common chemotherapy drug, than lean patients. An international team of researchers based this conclusion on a retrospective analysis of data from a large clinical trial.

Jul 03, 2020

Breast cancer patients who are overweight or obese might benefit less from treatment with docetaxel, a common chemotherapy drug, than lean patients. An international team of researchers based this conclusion on a retrospective analysis of data from a large clinical trial.

Jul 03, 2020

 

This is a recording of the American Lung Association’s Lung Cancer Precision Medicine Summit which took place on June 18, 2020. Oncologists Dr. Erin Schenk and Dr. Ibiayi Dagogo-Jack discuss which precision medicine treatment is available for lung cancer patients and promising new research. Carly Ornstein, National Director of Lung Cancer Education, gives a high-level overview of precision medicine and discusses new resources.

Case Studies

Jun 24, 2020

Polycythemia vera is one of the myeloproliferative neoplasms that is distinguished by the uncontrolled production of blood cells and an increased red cell mass due to acquired JAK2 mutation. It has many complications and it might increase the risk of other tumors. However, it does not cause hypercalcemia and is rarely associated with parathyroid adenoma. Ahmed M. Abdalhadi and Mohamed A. Yassin report on a 64-year-old female with polycythemia vera found to have hypercalcemia due to parathyroid adenoma.

Jun 22, 2020

Durvalumab, a programmed cell death ligand 1 inhibitor, induces various immune-related adverse events (irAEs), including lung injury. However, diffuse alveolar hemorrhage (DAH) is a rare type of lung injury due to immune checkpoint inhibitors. A 76-year-old man with c-stage IIIA squamous cell carcinoma of the lung received maintenance durvalumab therapy after chemoradiotherapy. He developed dyspnea and malaise after 11 cycles of durvalumab. Chest computed tomography showed rapidly spreading bilateral ground-glass opacity in the lungs. We diagnosed DAH by hemosiderin-laden macrophages in bloody bronchoalveolar lavage fluid. Despite mechanical ventilation, steroids, and cyclophosphamide, he died of respiratory failure. The autopsy revealed that fresh and old bleeding areas coexisted, and neither pulmonary vasculitis nor diffuse alveolar damage was detected microscopically. Furthermore, CD3+ and CD8+ lymphocytes were observed in the lung interstitium, whereas CD20+ and CD4+ lymphocytes were scarcely detected. We report the first case of durvalumab-induced DAH. We should be alert to irAEs with DAH as a potential differential diagnosis of lung injury during durvalumab treatment.

Jun 19, 2020

Only three cases of patients suffering from a localized chronic form of Langerhans cell histiocytosis (LCH) successfully treated with radiofrequency ablation (RFA) have been published so far. This is the first case report of a patient with a localized chronic form of LCH of the femur, which was successfully treated with percutaneous image-guided RFA, and who was evaluated pre-RFA and followed up post-RFA for a period of 48 months, in order to validate the safety and efficacy of this method and to obtain imaging studies depicting the actual in situ changes taking place post-RFA. RFA was proved to be a safe and efficient method when treating patients with a localized chronic form of LCH.

Jun 19, 2020

Recent data suggest that BRCA mutation carriers younger than 40 may not benefit from mammography in addition to MRI. Our objective was to evaluate screening modalities utilized in a high-risk population. Clinicopathologic data were abstracted for patients followed in a high-risk clinic from 2007 to 2017.  Three patients were diagnosed younger than 40, 1 on a mammogram, and 2 on MRI. The patient diagnosed on mammogram had no prior MRI and the lesion was seen on follow-up MRI. Interval screening MRI identified DCIS in BRCA patients with a previous normal mammogram and cancers diagnosed on mammograms were all identified on follow-up MRI. These findings support further evaluation of MRI alone until age 40 in BRCA mutation carriers.